| Ytd | -78.32% | |
| 1y | -91.93% |
| Open | 3.95 | Prev Close | 4.11 | Low | 3.50 | High | 3.95 | Mkt Cap | 3.11M |
| Vol | 68.29K | Avg Vol | 1.02M | EPS | -14.10 | P/E | N/A | Forward P/E | -6.39 |
| Beta | 3.57 | Short Ratio | 0.56 | Inst. Own | 2.41% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 7.21 | 200-d Avg | 12.34 | 1yr Est | 3.00 |
NXL News
Company remains focused on its transition toward commercial revenue generation and the advancement o
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Enovis (NYSE: ENOV - Get Free Report) are bot
Gainers Stablecoin Development (AMEX:SDEV) shares moved upwards by 66.9% to $6.11 during Friday'
U.S. stocks climbed Friday, led by Nasdaq; September jobs missed forecasts, unemployment rose, oil f
Gainers NewGenIvf Group (NASDAQ:NIVF) stock moved upwards by 56.7% to $0.16 during Friday's pre
Synaptics surged 14.5% after amending its $123/share cash buyout by onsemi; AMOD led gainers, while
U.S. stocks edged higher Thursday; Nasdaq rose 0.37%, energy led gains, Accenture surged 18%, and Co
Nexalin Technology (NXL) stock surged 80% on massive volume following a 10-year South American distr
Gainers Nexalin Technology (NASDAQ:NXL) shares increased by 77.8% to $7.61 during Thursday's re
U.S. stocks slipped Thursday as the Dow fell over 200 points; energy and oil rose, Micron beat estim
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexali
Agreement establishes an initial 100-device commercialization program for the ANVISA-approved Nexali
Appointment as Senior Strategic Advisor marks the Company's expansion from clinical development towa
Nexalin Technology (NASDAQ: NXL - Get Free Report) and LogicMark (OTCMKTS:LGMKD - Get Free Report) a
Further analysis of ADAS-Cog data from the Company's randomized, sham-controlled clinical trial — pr
HOUSTON, TX, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company”
Gainers Gossamer Bio (NASDAQ:GOSS) shares moved upwards by 47.2% to $0.29 during Tuesday's pre-
Gainers ENDRA Life Sciences (NASDAQ:NDRA) shares rose 10.8% to $5.94 during Tuesday's after-mar
Gainers iTonic Holdings (NASDAQ:ITOC) stock increased by 8.1% to $0.3 during Friday's after-mar
Gainers Pulsenmore (NASDAQ:PLSM) shares increased by 171.2% to $10.47 during Monday's pre-marke
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 55.8% to $1.11 during Wednesday'
Dr. Victor Fontenelle Bastos de Lima, an investigator on Nexalin's recently completed Brazilian clin
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and cli
Accepted abstracts showcase Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform and clinica
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no
Study using Nexalin's proprietary DIFS™ 15 mA 77.5 Hz treatment platform demonstrated rapid, large-m
Nexalin reports Brazil trial gains in anxiety, depression and sleep, plus U.S. patent protection thr
The United States Patent and Trademark Office has issued U.S. Patent No. 12,629,519, titled: "Tr
Newly issued U.S. patent expected to provide core intellectual property protection through 2042, fur
The U.S. House of Representatives-approved report language, which was secured through the Company
U.S. House Appropriations Committee report language directs VA to support additional research evalua
Through the transaction, Nexalin has secured ownership of PONM and an exclusive license to the propr
Acquisition gives Nexalin control of AI-integrated remote patient-monitoring, clinical data-capture
The study, titled: "Modulating Default and Salience/Ventral Attention networks: Exploring the tr
Publication reports statistically significant improvement in sleep quality following treatment with
Nexalin Technology, Inc. (NASDAQ:NXL) (the "Company" or "Nexalin"), the leader in no
160-participant, triple-blinded, sham-controlled study designed to support planned De Novo FDA submi
HOUSTON, TX, April 15, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL) (the “Company
ORLANDO, FL, April 14, 2026 (GLOBE NEWSWIRE) -- RedChip Companies will host an investor webinar on A
IDEAYA Biosciences shares (NASDAQ: IDYA) jumped 18% in pre-market trading after announcing topline
BMC Psychiatry publication reports statistically significant reductions in self-injury behaviors and
Nexalin study shows reduced self-injury and depression in adolescents using DIFS, with brain connect
Nexalin Technology (NASDAQ: NXL - Get Free Report) and Algorhythm (NASDAQ: RIME - Get Free Report) a
Nexalin Technology, Inc. (NASDAQ: NXL - Get Free Report) saw a significant decline in short interest
Nexalin Technology (NASDAQ:NXL) reported quarterly losses of $(0.13) per share which missed the anal